A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.

ABSTRACT:

Background

Agents targeting the metabotropic glutamate receptor 4 have emerged as a potentially attractive new class of drugs for the treatment of Parkinson's disease (PD).

Objective

The objective of this study was to evaluate the efficacy and safety of foliglurax in reducing off time and dyskinesia in patients with PD.

Methods

This was a 28-day, multicenter, randomized, placebo-controlled, double-blind clinical trial of foliglurax 10 and 30 mg as adjunct to levodopa in 157 randomly assigned patients with PD and motor complications.

Results

Although dose-dependent decreases in daily awake off time were apparent following treatment with foliglurax, the change from baseline to day 28 in off time (primary endpoint) and dyskinesia (secondary endpoint) did not impro

SUBMITTER: Rascol O 

PROVIDER: S-EPMC9303267 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature